Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan

doi:10.1111/trf.16161

. 2021 Feb;61(2):356-360.

doi: 10.1111/trf.16161. Epub 2020 Oct 26.

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan

Ritsuko Kubota-Koketsu¹, Yutaka Terada², Mikihiro Yunoki³, Tadahiro Sasaki¹, Emi E Nakayama¹, Wataru Kamitani^{2

4}, Tatsuo Shioda¹

Affiliations

¹ Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
² Laboratory of Clinical Research on Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
³ Research and Development Division, Japan Blood Products Organization, Tokyo, Japan.
⁴ Department of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi, Japan.

PMID: 33104267
DOI: 10.1111/trf.16161

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan

Ritsuko Kubota-Koketsu et al. Transfusion. 2021 Feb.

. 2021 Feb;61(2):356-360.

doi: 10.1111/trf.16161. Epub 2020 Oct 26.

Authors

Ritsuko Kubota-Koketsu¹, Yutaka Terada², Mikihiro Yunoki³, Tadahiro Sasaki¹, Emi E Nakayama¹, Wataru Kamitani^{2

4}, Tatsuo Shioda¹

Affiliations

¹ Department of Viral Infections, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
² Laboratory of Clinical Research on Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Japan.
³ Research and Development Division, Japan Blood Products Organization, Tokyo, Japan.
⁴ Department of Infectious Diseases and Host Defense, Graduate School of Medicine, Gunma University, Maebashi, Japan.

PMID: 33104267
DOI: 10.1111/trf.16161

Abstract

Background: There are several types of coronaviruses that infect humans and cause disease. The latest is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is an emerging global threat with no current effective treatment. Normal intravenous immunoglobulin (N-IVIG) has been administered to coronavirus disease 2019 (COVID-19) patients to control severe inflammation and the cellular immune response. However, the neutralizing activity of N-IVIG against SARS-CoV-2 has not yet been fully evaluated. The aim of this study was to determine whether N-IVIG manufactured before the start of the COVID-19 pandemic contained IgG antibodies against the circulating human coronaviruses (HCoVs) that cross-react with the highly pathogenic coronaviruses SARS-CoV-1, Middle East respiratory syndrome coronavirus (MERS-CoV), and SARS-CoV-2. No cases of SARS-CoV-1 or MERS-CoV have been reported in Japan.

Study design and methods: The neutralizing and binding activities of N-IVIG against SARS-CoV-1, MERS-CoV, SARS-CoV-2, HCoV 229E, and HCoV OC43 were evaluated. Nine N-IVIG lots manufactured between 2000 and 2018, derived from donors in Japan, were tested. Binding activity was evaluated by indirect immunofluorescence assay.

Results: None of the N-IVIG lots tested displayed neutralizing or binding activity against SARS-CoV-1, MERS-CoV, or SARS-CoV-2. However, they displayed substantial neutralizing and binding activity against HCoV OC43 and weak neutralizing and substantial binding activity against HCoV 229E.

Conclusion: N-IVIG derived from healthy donors in Japan before the start of the COVID-19 pandemic had no direct effect against SARS-CoV-2. Further studies are warranted to determine the effects of N-IVIG manufactured after the start of the COVID-19 pandemic against SARS-CoV-2.

Keywords: COVID-19; IVIG; MERS; SARS; binding; coronavirus; neutralization.

PubMed Disclaimer

Cited by

Preclinical study of a DNA vaccine _targeting SARS-CoV-2.
Hayashi H, Sun J, Yanagida Y, Otera T, Kubota-Koketsu R, Shioda T, Ono C, Matsuura Y, Arase H, Yoshida S, Nakamaru R, Ju N, Ide R, Tenma A, Kawabata S, Ehara T, Sakaguchi M, Tomioka H, Shimamura M, Okamoto S, Amaishi Y, Chono H, Mineno J, Komatsuno T, Saito Y, Rakugi H, Morishita R, Nakagami H. Hayashi H, et al. Curr Res Transl Med. 2022 Sep;70(4):103348. doi: 10.1016/j.retram.2022.103348. Epub 2022 Apr 20. Curr Res Transl Med. 2022. PMID: 35489099 Free PMC article.
Function matters: Coronavirus cross-binding antibodies do not cross-neutralize.
Farcet MR, Schwaiger J, Karbiener M, Kreil TR. Farcet MR, et al. Front Med (Lausanne). 2022 Aug 2;9:924426. doi: 10.3389/fmed.2022.924426. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35983096 Free PMC article.
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.
Zsichla L, Müller V. Zsichla L, et al. Viruses. 2023 Jan 7;15(1):175. doi: 10.3390/v15010175. Viruses. 2023. PMID: 36680215 Free PMC article. Review.
Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters.
Piano Mortari E, Pulvirenti F, Marcellini V, Terreri S, Salinas AF, Ferrari S, Di Napoli G, Guadagnolo D, Sculco E, Albano C, Guercio M, Di Cecca S, Milito C, Garzi G, Pesce AM, Bonanni L, Sinibaldi M, Bordoni V, Di Cecilia S, Accordini S, Castilletti C, Agrati C, Quintarelli C, Zaffina S, Locatelli F, Carsetti R, Quinti I. Piano Mortari E, et al. Front Immunol. 2023 May 25;14:1194225. doi: 10.3389/fimmu.2023.1194225. eCollection 2023. Front Immunol. 2023. PMID: 37304298 Free PMC article.
Terpenes and cannabidiol against human corona and influenza viruses-Anti-inflammatory and antiviral in vitro evaluation.
Chatow L, Nudel A, Eyal N, Lupo T, Ramirez S, Zelinger E, Nesher I, Boxer R. Chatow L, et al. Biotechnol Rep (Amst). 2024 Jan 17;41:e00829. doi: 10.1016/j.btre.2024.e00829. eCollection 2024 Mar. Biotechnol Rep (Amst). 2024. PMID: 38318445 Free PMC article.

See all "Cited by" articles

References

REFERENCES

1. The International Committee on Taxonomy of Viruses. Coronavirus, ICTV 9th report (2011). https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-.... Accessed September 1, 2020.
1. Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-544.
1. Bloch EM, Shoham S, Casadevall S, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757-2765.
1. Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020. May 1; https://doi.org/10.1002/jmv.25961. [Epub ahead of print].
1. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80-90.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

This study was founded by Japan Blood Products Organization and was conducted in a collaborative research project between Osaka University and the Japan Blood Products Organization

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wiley
Miscellaneous
- NCI CPTAC Assay Portal

[1] The International Committee on Taxonomy of Viruses. Coronavirus, ICTV 9th report (2011). https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-.... Accessed September 1, 2020.

[2] The International Committee on Taxonomy of Viruses. Coronavirus, ICTV 9th report (2011). https://talk.ictvonline.org/ictv-reports/ictv_9th_report/positive-sense-.... Accessed September 1, 2020.

[3] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-544.

[4] Coronaviridae Study Group of the International Committee on Taxonomy of Viruses. The species severe acute respiratory syndrome-related coronavirus classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol. 2020;5:536-544.

[5] Bloch EM, Shoham S, Casadevall S, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757-2765.

[6] Bloch EM, Shoham S, Casadevall S, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130:2757-2765.

[7] Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020. May 1; https://doi.org/10.1002/jmv.25961. [Epub ahead of print].

[8] Rajendran K, Krishnasamy N, Rangarajan J, et al. Convalescent plasma transfusion for the treatment of COVID-19: Systematic review. J Med Virol. 2020. May 1; https://doi.org/10.1002/jmv.25961. [Epub ahead of print].

[9] Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80-90.

[10] Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: A systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80-90.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan

Affiliations

Neutralizing and binding activities against SARS-CoV-1/2, MERS-CoV, and human coronaviruses 229E and OC43 by normal human intravenous immunoglobulin derived from healthy donors in Japan

Authors

Affiliations

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous

Abstract

Similar articles

Cited by

References

REFERENCES

Publication types

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous